Most subjects treated with ipragliflozin did not present with CKD, exhibiting a mean baseline eGFR of 81.3 mL/min/1.73 m2, which was comparable to those not treated with an SGLT2 inhibitor. Here, SLC5A2 is linked to chronic kidney disease.